Atlas Trials

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT07480850 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07480850
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Start date
2026-01-01
Primary completion
2028-01-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.